EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncological Outcome for 83 Consecutive Patients With Malignant Peripheral Nerve Sheath Tumors Treated at a Tertiary Referral Centre

Hannah V M Yeomans iD, Kira C Lloyd iD, Felix Haglund de Flon iD, Sharmineh Mansoori iD, Panagiotis Tsagkozis iD, Christina M Linder Stragliotto iD

Cancer Reports · 2025-11 · 8 (11)

DOI: 10.1002/cnr2.70406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 21.11.2025. Verfasst von Hannah V M Yeomans und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Cancer, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Neurofibrosarcoma, Nerve Sheath Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bernt Katinas Memorial Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft tissue sarcomas with a high risk of recurrence and a poor prognosis, and there is a lack of knowledge regarding long‐term follow‐up and response to oncological treatment.

Aims

The aim of this study was to investigate what treatment the patients received and to examine the outcome for patients with MPNST. Methods and Results This is a retrospective study of patients treated for MPNST at Karolinska University Hospital between 2003 and 2022. Data regarding surgical and oncological treatment and follow‐up were collected. Eighty‐three patients were identified and included in the study. Tumor grade is available for 72 patients, of which 64 had high‐grade tumors. Seventy‐nine patients were primarily operated on. Twelve patients presented with distant metastases at diagnosis. Another 37 patients developed local recurrence or distant metastases during follow‐up; the median time from surgery to recurrence was 10.5 months (1–95 months, n = 36). The overall mortality rate during the study period was 44% ( n = 82). Twenty‐seven patients received palliative systemic treatment. The most used therapy for first‐line palliative systemic treatment was doxorubicin and ifosfamide. The disease control rate for first‐line treatment was 33% ( n = 21). The mean overall survival for the cohort was 132 months (95% CI 107–157 months).

Conclusion

Forty‐five percent of the patients in this material were diagnosed with recurrent disease and most patients treated with palliative systemic therapy experienced brief disease control following treatment. Among patients with MPNST treated with first‐line palliative oncological treatment, doxorubicin and ifosfamide have the highest disease control rates. The study also identified a few patients with long‐term treatment responses, with four patients alive more than 2 years after starting palliative oncological treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalNeurofibrosarcomaNerve Sheath NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTertiary Care CentersAgedFollow-Up StudiesYoung AdultTreatment OutcomeAdolescentPalliative CarePrognosisSurvival RateDoxorubicinIfosfamideAged, 80 and overNeoplasm Grading

Stichwörter der Autor:innen

MPNSTneurofibromatosis type 1oncological treatmentsoft tissue sarcoma

Substanzen

DoxorubicinIfosfamide

Autor:innen und Institutionen

  • Department of Breast Cancer, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Acute and Reparative Medicine, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Hannah V M Yeomans, Kira C Lloyd, Felix Haglund de Flon, Sharmineh Mansoori, Panagiotis Tsagkozis, Christina M Linder Stragliotto

Förderung

  • Bernt Katinas Memorial Fund

Zitieren

APA

Yeomans, H. V. M., Lloyd, K. C., de Flon, F. H., Mansoori, S., Tsagkozis, P., & Linder Stragliotto, C. M. (2025). Oncological Outcome for 83 Consecutive Patients With Malignant Peripheral Nerve Sheath Tumors Treated at a Tertiary Referral Centre. Cancer Reports, 8(11). https://doi.org/10.1002/cnr2.70406

Vancouver

Yeomans HVM, Lloyd KC, de Flon FH, Mansoori S, Tsagkozis P, Linder Stragliotto CM. Oncological Outcome for 83 Consecutive Patients With Malignant Peripheral Nerve Sheath Tumors Treated at a Tertiary Referral Centre. Cancer Reports. 2025;8(11). doi:10.1002/cnr2.70406

BibTeX
@article{Yeomans2025,
  author = {Yeomans, Hannah V M and Lloyd, Kira C and de Flon, Felix Haglund and Mansoori, Sharmineh and Tsagkozis, Panagiotis and Linder Stragliotto, Christina M},
  title = {Oncological Outcome for 83 Consecutive Patients With Malignant Peripheral Nerve Sheath Tumors Treated at a Tertiary Referral Centre},
  journal = {Cancer Reports},
  year = {2025},
  volume = {8},
  number = {11},
  doi = {10.1002/cnr2.70406}
}
Kostenlos starten →